BioNxt Solutions closes C$2M private placement to fund European MS programme
What's the deal? BioNxt SolutionsDealroom has a profile for this one. Try Dealroom →, a Vancouver-based bioscience company, has closed a non-brokered private placement raising C$2 million (about $1.4 million).
It issued 6,060,606 units at C$0.33 each. Each unit pairs one common share with one warrant exercisable at C$0.50 for 24 months.
BioNxt plans to direct the proceeds toward its European research, development, and operations, plus working capital.
Why now? The financing used Canada's Listed Issuer Financing exemption, which lets the shares trade without a hold period.
The company is also extending its unsecured convertible debentures, with closing expected around July 10, 2026.
What could go wrong? Raising capital came at a cost: BioNxt paid C$120,000 in finder's fees and issued 363,636 finder's warrants.
The warrants could dilute existing shareholders if exercised. The pending debenture extension still needs corporate approvals.
The signal: BioNxt's lead candidate is a sublingual thin-film version of cladribine for multiple sclerosis, and this raise keeps that European-focused programme funded as the early-stage company pushes toward regulatory milestones. The reliance on Canada's Listed Issuer Financing exemption — which sidesteps the usual hold period — underlines how micro-cap biotechs are leaning on lighter-touch placements to bridge late-stage development without a full prospectus offering.
Read more: streetinsider.com
Image credit: "chemistry bottles with liquid inside" by zhouxuan12345678 is licensed under CC BY-SA 2.0. To view a copy of this license, visit https://creativecommons.org/licenses/by-sa/2.0/.
